
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is a promising, yet high-risk investment opportunity. With the potential to address devastating diseases with its gene therapy treatments, the company has a strong pipeline and positive outlook. Continued progress and potential regulatory validation in the UK for AMT-130, as well as upcoming Phase 1/2a trial data for AMT-260, could serve as near-term catalysts for the company. However, there are financial and clinical risks inherent in investing in a clinical-stage company with no revenue-generating products on the market. Investors must carefully weigh the potential for success against these risks when considering investment in uniQure's stock.
Bears say
uniQure is a gene therapy company with a focus on developing treatments for genetic and other debilitating diseases. Despite strong collaborations and a diverse pipeline, there is a high level of risk associated with the company's clinical trials and potential regulatory challenges. Financial concerns, such as the need for additional funding, further exacerbate the company's risk profile. Additionally, intellectual property disputes and stock price volatility are potential risks that could affect the achievement of the current target price.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares